Teva has received FDA approval for once monthly injectable schizophrenia drug Weltruza. The announcement sent Teva shares ...
With a Friday go-ahead from the FDA, another key piece of Teva’s innovation revamp strategy has fallen into place, further ...
Investor's Business Daily on MSN
Teva, already up 26% this year, surges again on first-of-its-kind approval
Teva stock surged Friday after the FDA approved its schizophrenia drug, a once-monthly injectable treatment for the disease.
Teva stock is a "Hold" as its "Pivot to Growth" strategy shows early promise but requires further execution. Click for more ...
Asianet Newsable on MSN
Teva stock hits fresh 52-week high as FDA approves monthly schizophrenia shot
The U.S. Food and Drug Administration approved Weltruza as an extended-release injectable suspension for adults with ...
The FDA has approved olanzapine extended-release injectable suspension (Weltruza; Teva Pharmaceuticals), a once-monthly ...
Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Limited (NYSE:TEVA), agreed to serve as the stalking-horse bidder for substantially all assets of BioXcel ...
WELTRUZA ™ (olanzapine) for extended-release injectable suspension is the first and only once-monthly subcutaneous ...
Israeli pharmaceutical giant Teva receives FDA approval for WELTRUZA, a new long-acting injection for schizophrenia that ...
Already sharing the load on two biosimilar assets, Teva Pharmaceutical and Samsung Bioepis have elected to take their ...
TAPI has 4,100 employees worldwide including 650 in Israel. The layoffs will mainly affect the Teva Tech plant in Neot Hovav ...
Teva Pharmaceutical Industries (NYSE:TEVA) said the U.S. Food and Drug Administration has approved WELTRUZA, a once-monthly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results